全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Jennifer N. Clements , Tiffaney Threatt , Eileen Ward ...
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2017, Vol.56 (5), pp.449-458
摘要:... Several studies have been conducted and completed evaluating blood samples for the pharmacokinetics of insulin glargine U-300 and euglycemic clamp procedures for the pharmacodynamics. This concentrated insulin has a low within-day variability and high day-to-day reproduci...
作者:Nicolas Grégoire , Vincent Aranzana-Climent , Sophie Magréault ...
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2017, Vol.56 (12), pp.1441-1460
摘要:In this review, we provide an updated summary on colistin pharmacokinetics and pharmacodynamics. Colistin is an old molecule that is frequently used as last-line treatment for infections caused by multidrug-resistant Gram-negative bacteria. Colistin is a decapeptide administered ...
作者:Maria Rosario , Nathanael L. Dirks , Catherine Milch ...
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2017, Vol.56 (11), pp.1287-1301
摘要:... This article provides a comprehensive review of the clinical pharmacokinetics, pharmacodynamics, exposure–efficacy relationships, and immunogenicity of vedolizumab.
作者:Robert C. Owens , Catharine C. Bulik , David R. Andes
来源:[J].Diagnostic Microbiology & Infectious Disease(IF 2.26), 2018
摘要:... These guidelines recommend that stewardship programs employ the science of pharmacokinetics–pharmacodynamics (PK-PD) as well as adopting computerized decision support technologies when possible. The United States Food and Drug Administration have adopted PK-PD as a corners...
作者:Sara Cascone , Gaetano Lamberti , Ornella Piazza ...
来源:[J].European Journal of Pharmaceutical Sciences(IF 2.987), 2018, Vol.111, pp.20-28
摘要:... The aims of this work are to propose and validate a physiologically based pharmacokinetic model capable to predict both the pharmacokinetics and pharmacodynamics of remifentanil, and to take into account the inter-individual differences among the patients (such as height and ...
作者:Ling Song , Xueting Yao , Yang Liu ...
来源:[J].European Journal of Pharmaceutical Sciences(IF 2.987), 2020, Vol.147
摘要:... To predict human pharmacokinetics/pharmacodynamics (PK/PD) characteristics of janagliflozin. To design optimal starting dose and effective dose for janagliflozin first-in-human (FIH) study.(#br)Methods(#br)Animal PK/PD properties of janagliflozin were obtained from preclinic...
作者:Daniel Gonzalez , James M. Chamberlain , Jeffrey T. Guptill ...
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2017, Vol.56 (8), pp.941-951
摘要:Lorazepam is one of the preferred agents used for intravenous treatment of status epilepticus (SE). We combined data from two pediatric clinical trials to characterize the population pharmacokinetics of intravenous lorazepam in infants and children aged 3 months to 17 years with ...
作者:William M. Greenberg , Leslie Citrome
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2017, Vol.56 (5), pp.493-503
摘要:Lurasidone hydrochloride, a benzisothiazol derivative, is a second-generation (atypical) antipsychotic agent that has received regulatory approval for the treatment of schizophrenia in the US, Canada, the EU, Switzerland, and Australia, and also for bipolar depression in the...
作者:Weifeng Tang , Alex McCormick , Jianguo Li ...
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2017, Vol.56 (7), pp.689-702
摘要:Cediranib potently and selectively inhibits all three vascular endothelial growth factor receptors (VEGFR-1, -2 and -3), and clinical studies have shown that it is effective in patients with ovarian cancer at a dose of 20 mg/day. Cediranib is absorbed moderately slowly; a hi...
作者:Elisabeth I. Minder , Jasmin Barman-Aksoezen , Xiaoye Schneider-Yin
来源:[J].Clinical Pharmacokinetics(IF 6.109), 2017, Vol.56 (8), pp.815-823
摘要:Afamelanotide, the first α-melanocyte-stimulating hormone (MSH) analogue, synthesized in 1980, was broadly investigated in all aspects of pigmentation because its activity and stability were higher than the natural hormone. Afamelanotide binds to the melanocortin-1 receptor ...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×